In vitro and in vivo anti-tumor efficacy of 10-hydroxycamptothecin polymorphic nanoparticle dispersions: Shape- and polymorph-dependent cytotoxicity and delivery of 10-hydroxycamptothecin to cancer cells

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 4, 2016, Pages 881-891

  Wang, Hongdi ^a   Feng, Jialing ^a   Liu, Guijin ^a   Chen, Baoqiong ^b   Jiang, Yanbin ^a   Xie, Qiuling ^b,c  

^a SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

^b National Engineering Research Centre of Genetic Medicine   (China)

^c JINAN UNIVERSITY   (China)

Author keywords

10 hydroxycamptothecin; Antitumor efficacy; Cancer therapy; Cytotoxicity; Polymorph; Shape

Indexed keywords

DISEASES; DISPERSIONS; DISSOLUTION; DRUG DOSAGE; HISTOLOGY; HOMOGENIZATION METHOD; NANOPARTICLES; NEEDLES; POLYMORPHISM; TISSUE; TUMORS;

10 HYDROXYCAMPTOTHECIN (HCPT); ANTI-TUMOR EFFICACY; CANCER THERAPY; HIGH PRESSURE HOMOGENIZATION; NANO-PARTICLE DISPERSIONS; SHAPE; SHAPED NANOPARTICLES; SUPERCRITICAL ANTI-SOLVENT TECHNIQUES;

CYTOTOXICITY;

10 HYDROXYCAMPTOTHECIN; NANOPARTICLE; 10-HYDROXYCAMPTOTHECIN; CAMPTOTHECIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOCHEMICAL ANALYSIS; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CELL PROLIFERATION; CELL VIABILITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOTOXICITY; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE HOMOGENIZATION; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MORPHOLOGY; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYMORPHIC NANOPARTICLE DISPERSION; PRESSURE; SCANNING ELECTRON MICROSCOPY; SUPERCRITICAL FLUID; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION; ANALOGS AND DERIVATIVES; CHEMISTRY; NEOPLASMS; PATHOLOGY; SOLUBILITY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

CAMPTOTHECIN; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS; PARTICLE SIZE; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 84961134999     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.12.373     Document Type: Article

References (56)

1. Williams H.D., Trevaskis N.L., Charman S.A., Shanker R.M., Charman W.N., Pouton C.W., et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev 2013, 65:315-499.
2. Gong C.Y., Shi S., Wang X.H., Wang Y.J., Fu S.Z., Dong P.W., et al. Novel composite drug delivery system for honokiol delivery: self-assembled poly(ethylene glycol)-poly (ε-caprolactone) -poly(ethylene glycol) micelles in thermosensitive poly(ethylene glycol)-poly (ε-caprolactone) -poly(ethylene glycol) hydrogel. J Phys Chem B 2009, 113:10183-10188.
3. Gong C.Y., Wei X.W., Wang X.H., Wang Y.J., Guo G., Mao Y.Q., et al. Biodegradable self-assembled PEG-PCL-PEG micelles for hydrophobic honokiol delivery: I. Preparation and characterization. Nanotechnology 2010, 21:215103.
4. Gao X., Wang B.L., Wei X.W., Men K., Zheng F.J., Zhou Y.F., et al. Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer. Nanoscale 2012, 4:7021-7030.
5. Guo G., Fu S.Z., Zhou L.X., Liang H., Fan M., Luo F., et al. Preparation of curcumin loaded poly(3 -caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) nanofibers and their in vitro antitumor activity against Glioma 9L cells. Nanoscale 2011, 3:3825-3832.
6. Peer D., Karp J.M., Hong S., FaroKHzad O.C., Margalit R., Langer R. Nano-carriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
7. Jain R.K., Stylianopoulos T. Delivering nano-medicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664.
8. Kim B.Y.S., Rutka J.T., Chan W.C.W. Current concepts: nano-medicine. N Engl J Med 2010, 363:2434-2443.
9. Rosi N.L., Giljohann D.A., Thaxton C.S., Lytton-Jean A.K.R., Han M.S., Mirkin C.A. Oligonucleotide- modified gold nanoparticles for intracellular gene regulation. Science 2006, 312:1027-1030.
10. Li Z., Hüve J., Krample C., Luppi G., Tsotsalas M., Klingauf J., et al. Internalization pathways of anisotropic disc-shaped zeolite L nanocrystals with different surface properties in heLa cancer cells. Small 2013, 9:1809-1820.
11. Rejman J., Oberle V., Zuhorn I.S., Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem J 2004, 377:159-169.
12. Chithrani B.D., Ghazani A.A., Chan W.C.W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006, 6:662-668.
13. Thevenot P., Cho J., Wavhal D., Timmons R.B., Tang L.P. Surface chemistry influences cancer killing effect of TiO2 nanoparticles. Nanomedicine 2008, 4:226-236.
14. Blagden N., de Matas M., Gavan P.T., York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 2007, 59:617-630.
15. Aguiar A.J., Zelmer J.E. Dissolution behaviour of polymorphs of chloramphenicol palmitate and mefenamic acid. J Pharm Sci 1969, 58:983-987.
16. Raw A.S., Furness M.S., Gill D.S., Adams R.C., Holcombe F.O., Yu L.X. Regulatory considerations of pharmaceutical solid polymorphism in abbreviated new drug applications (ANDAs). Adv Drug Deliv Rev 2004, 56:397-414.
17. Purohit R., Venugopalan P. Polymorphism: an overview. Resonance 2009, 14:882-893.
18. Kordikowski A., Shekunov T., York P. Polymorph control of sulfathiazole in supercritical CO2. Pharm Res 2001, 18:682-687.
19. De Gioannis B., Jestin P., Subra P. Morphology and growth control of griseofulvin recrystallized by compressed carbon dioxide as anti-solvent. J Cryst Growth 2004, 262:519-526.
20. Jiang Y.B., Sun W.L., Wang W. Recrystallization and micronization of 10-hydroxycamptothecin by supercritical anti-solvent process. Ind Eng Chem Res 2012, 51:2596-2602.
21. Bolten D., Türk M. Micronizsation of carbamazepine through rapid expansion of supercritical solution (RESS). J Supercrit Fluid 2012, 62:32-40.
22. Rossmann M., Braeuer A., Leipertz A., Schluecker E. Manipulating the size, the morphology and the polymorphism of acetaminophen using supercritical anti-solvent (SAS) precipitation. J Supercrit Fluid 2013, 82:230-237.
23. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985, 260:14873-14878.
24. Rothenberg M.L. Topoisomerase I, inhibitors: review and update. Ann Oncol 1997, 8:837-855.
25. Hong M., Zhu S., Jiang Y., Tang G., Pei Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J Control Release 2009, 133:96-102.
26. Hertzberg R.P., Caranfa M.J., Holden K.G., Jakas D.R., Gallagher G., Mattern M.R., et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989, 32:715-720.
27. Wani M.C., Ronman P.E., Lindley J.T., Wall M.E. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J Med Chem 1980, 23:554-560.
28. He X.G., Lu W., Jiang X.Q., Cai J.C., Zhang X.W., Ding J. Synthesis and biological evaluation of bis and monocarbonate prodrugs of 10-hydroxycamptothecins. Bioorg Med Chem 2004, 12:4003-4008.
29. Wong B.S., Yoong S.L., Jagusiak A., Panczyk T., Ho H.K., Ang W.H., et al. Carbon nanotubes for delivery of small molecule drugs. Adv Drug Deliv Rev 2013, 65:1964-2015.
30. Wang W., Liu G.J., Wu J., Jiang Y.B. Co-precipitation of 10-hydroxycamptothecin and poly (L-lactic acid) by supercritical CO2 anti-solvent process using dichloromethane/ethanol co-solvent. J Supercrit Fluid 2013, 74:137-144.
31. Liu G.J., Wang H.D., Jiang Y.B. Recrystallization and micronization of camptothecin by the supercritical anti-solvent process: influence of solvents. Ind Eng Chem Res 2013, 52:15049-15056.
32. Wang W., Heideman L., Chung C.S., Pelling J.C., Koehler K.J., Birt D.F. Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol Carcinog 2000, 28:102-110.
33. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
34. Schwartz G.K., Shah M.A. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005, 23:9408-9421.
35. Luo X.M., Jia G.Q., Song H.X., Liu C.Y., Wu G.N., Li X.H. Promoting antitumor activities of hydroxycamptothecin by encapsulation into acid-Labile nanoparticles using electrospraying. Pharm Res 2014, 31:46-59.
36. Zhang L.Y., Yang M., Wang Q., Li Y., Guo R., Jiang X.Q., et al. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J Control Release 2007, 119:153-162.
37. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53:283-318.
38. Lu J., Li Z.X., Zink J.I., Tamanoi F. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine 2012, 8:212-220.
39. Grandhi B.K., Thakkar A., Wang J., Prabhu S. A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions. Cancer Prev Res (Phila) 2013, 6:1015-1025.
40. Siddiqui I.A., Bharali D.J., Nihal M., Adhami V.M., Khan N., Chamcheu J.C., et al. Excellent anti-proliferative and pro-apoptotic effects of (-) -epigallocatechin -3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo. Nanomedicine 2014, 10:1619-1626.
41. Higuchi W.I., Bernardo P.D., Mehta S.C. Polymorphism and drug availability. II. Dissolution rate behavior of the polymorphic forms of sulfathiazole and methylprednisolone. J Pharm Sci 1967, 56:200-207.
42. Hörter D., Dressman J.B. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 2001, 46:75-87.
43. Christoffersen M.R., Balic-Zunic T., Christoffersen J. Kinetics and mechanisms of dissolution and growth of acicular triclinic calcium pyrophosphate dihydrate crystals. Cryst Growth Des 2002, 2:567-571.
44. Ho R., Naderi M., Heng J.Y.Y., Williams D.R., Thielmann F., Bouza P., et al. Effect of milling on particle shape and surface energy heterogeneity of needle-shaped crystals. Pharm Res 2012, 29:2806-2816.
45. Singhal D., Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Deliv Rev 2004, 56:335-347.
46. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006, 6:789-802.
47. Darzynkiewicz Z., Bruno S., Bino G.D., Traganos F. The cell cycle effects of camptothecin. Ann N Y Acad Sci 1996, 803:93-100.
48. Ping Y.H., Lee H.C., Lee J.Y., Wu P.H., Ho L.K., Chi C.W., et al. Anticancer effects of low-dose 10-hydroxycamptothecin in human colon cancer. Oncol Rep 2006, 15:1273-1279.
49. Zhang X., Qing C., Xu B. Apoptosis induction and cell cycle perturbation in human hepatoma Hep G2 cells by 10-hydroxycamptothecin. Anti-Cancer Drugs 1999, 10:569-576.
50. Napierska D., Thomassen L.C.J., Rabolli V., Lison D., Gonzalez L., Kirsch-Volders M., et al. Size-dependent cytotoxicity of monodisperse silica nanoparticles in human endothelial cells. Small 2009, 5:846-853.
51. Gratton S.E.A., Ropp P.A., Pohlhaus P.D., Luft J.C., Madden V.J., Napier M.E., et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci 2008, 105:11613-11618.
52. Huang X.L., Li L.L., Liu T.L., Hao N.J., Liu H.Y., Chen D., et al. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano 2011, 5:5390-5399.
53. Li W., Zhang X.J., Hao X.J., Jie J.S., Tian B.S., Zhang X.H. Shape design of high drug payload nanoparticles for more effective cancer therapy. Chem Commun 2013, 49:10989-10991.
54. 2 nanoparticles in living lung epithelial cells. Small 2011, 7:514-523.
55. Zhang H., Hollis C.P., Zhang Q., Li T.L. Preparation and antitumor study of camptothecin nanocrystals. Int J Pharm 2011, 415:293-300.
56. Koshkina N., Waldrep J., Knight V. Camptothecins and lung cancer: improved delivery systems by aerosol. Curr Cancer Drug Targets 2003, 3:251-264.